Please use this identifier to cite or link to this item:
|Title:||Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.|
|Other Authors:||Dear, Anthony|
Single Nucleotide Polymorphism
Cytochrome P-450 CYP2C19
Department of Cardiology, Epworth Hospital, Richmond, Melbourne, Australia
Cardiac Sciences Clinical Institute, Epworth HealthCare, Victoria, Australia
|Citation:||Heart Lung Circ. 2011 Oct;20(10):657-8.|
|Abstract:||Clopidogrel is a widely used anti-platelet agent for the prevention of arterial thrombosis. Clopidogrel is administered as a pro-drug and metabolised to its active metabolite by the hepatic cytochrome P450 2C19 (CYP2C19) enzyme. The active metabolite is responsible for the anti-platelet activity of clopidogrel. Recent studies demonstrate that single nucleotide polymorphisms (SNPs) in the gene for CYP2C19 result in significantly reduced production of the active metabolite of clopidogrel. Additional studies demonstrate that patients with SNPs in the CYP2C19 gene, including CYP2C19*2,*3,*4, and *5, have reduced production of the active metabolite of clopidogrel, reduced inhibition of platelet aggregation and increased incidence of coronary, cerebrovascular, and coronary stent thrombosis. We have been interested in determining the CYP2C19 genotype in cases of coronary stent thrombosis whilst on clopidogrel treatment and provide two case reports of coronary stent thrombosis whilst taking clopidogrel with subsequent CYP2C19 genotyping. As patients at risk of atherothrombosis in general, and stent thrombosis in particular, may be receiving or considered for anti-platelet therapy including clopidogrel, genotyping for CYP2C19 SNP's may be of benefit in the selection of appropriate anti-platelet therapy.|
|Journal Title:||Heart, Lung and Circulation|
|Type of Clinical Study or Trial:||Case reports|
|Appears in Collections:||Cardiac Sciences|
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.